keyword
MENU ▼
Read by QxMD icon Read
search

heart failure treatment

keyword
https://www.readbyqxmd.com/read/28350620/treatment-of-uncomplicated-hypertension-is-associated-with-a-reduction-in-cardiovascular-mortality-a-korean-national-cohort-study
#1
Chan J Lee, Jinseub Hwang, Jaewon Oh, Sang-Hak Lee, Seok-Min Kang, Donghoon Choi, Hyeon-Chang Kim, Sungha Park
BACKGROUND: Although the benefit of hypertension treatment is well established in high-risk patients, there is a paucity of evidence regarding the benefit of treatment in patients with uncomplicated hypertension. METHODS: Hypertensive adult patients were selected from the Korea National Health Insurance Sample Cohort in 2002 and were followed until 2013. Patients with a diagnosis of heart failure, coronary artery disease, stroke, malignancy, diabetes, or chronic kidney disease were excluded...
May 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28346572/effectiveness-of-cardiac-rehabilitation-for-prevention-and-treatment-of-sarcopenia-in-patients-with-cardiovascular-disease-a-retrospective-cross-sectional-analysis
#2
H Harada, H Kai, H Niiyama, Y Nishiyama, A Katoh, N Yoshida, Y Fukumoto, H Ikeda
OBJECTIVE: Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, with the risk of frailty and poor quality of life. This study aimed to clarify the clinical characteristics of sarcopenia and to investigate the effects of comprehensive cardiac rehabilitation (CCR), including nutrition, physical exercise and medication, in patients with cardiovascular disease (CVD). METHODS: We retrospectively studied 322 inpatients with CVD (age 72±12 years)...
2017: Journal of Nutrition, Health & Aging
https://www.readbyqxmd.com/read/28346238/management-of-hypertension-in-2017-targets-and-therapies
#3
Monica Ahluwalia, Sripal Bangalore
PURPOSE OF REVIEW: Approximately one-fourth of the adult population is diagnosed with hypertension, which has been associated with increased cardiovascular morbidity and mortality including cardiovascular death, myocardial infarction, heart failure and stroke. Early detection and treatment is a key and can lead to a significant reduction in cardiovascular morbidity and mortality. RECENT FINDINGS: In this review, we discuss the management and treatment strategies in patients with hypertension in the current era...
March 24, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/28346005/plasma-coenzyme-q10-concentration-antioxidant-status-and-serum-n-terminal-pro-brain-natriuretic-peptide-concentration-in-dogs-with-various-cardiovascular-diseases-and-the-effect-of-cardiac-treatment-on-measured-variables
#4
Alenka Nemec Svete, Barbara Verk, Alenka Seliškar, Katerina Tomsič, Petra Jazbec Križman, Aleksandra Domanjko Petrič
OBJECTIVE To determine the plasma total antioxidant capacity, erythrocyte superoxide dismutase activity, whole blood glutathione peroxidase activity, and plasma coenzyme Q10 (CoQ10) concentration in dogs with various stages of cardiovascular diseases and in healthy dogs; assess the influence of cardiac treatment on the levels of antioxidant variables, plasma CoQ10 concentration, and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, and determine any correlation between the disease severity (NT-proBNP concentration) and antioxidant variables or CoQ10 concentration...
April 2017: American Journal of Veterinary Research
https://www.readbyqxmd.com/read/28345491/a-comparison-of-toxicities-in-acute-myeloid-leukemia-patients-with-and-without-renal-impairment-treated-with-decitabine
#5
Lauren B Levine, Julianna Vf Roddy, Miryoung Kim, Junan Li, Gary Phillips, Alison R Walker
Purpose There are limited data regarding the clinical use of decitabine for the treatment of acute myeloid leukemia in patients with a serum creatinine of 2 mg/dL or greater. Methods We retrospectively evaluated 111 patients with acute myeloid leukemia who had been treated with decitabine and compared the development of toxicities during cycle 1 in those with normal renal function (creatinine clearance greater than or equal to 60 mL/min) to those with renal dysfunction (creatinine clearance less than 60 mL/min)...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28345190/new-medicinal-products-for-chronic-heart-failure-advances-in-clinical-trial-design-and-efficacy-assessment
#6
REVIEW
Martin R Cowie, Gerasimos S Filippatos, Maria de Los Angeles Alonso Garcia, Stefan D Anker, Anna Baczynska, Daniel M Bloomfield, Maria Borentain, Karsten Bruins Slot, Maureen Cronin, Pieter A Doevendans, Amany El-Gazayerly, Claudio Gimpelewicz, Narimon Honarpour, Salim Janmohamed, Heidi Janssen, Albert M Kim, Dominik Lautsch, Ian Laws, Martin Lefkowitz, Jose Lopez-Sendon, Alexander R Lyon, Fady I Malik, John J V McMurray, Marco Metra, Santiago Figueroa Perez, Marc A Pfeffer, Stuart J Pocock, Piotr Ponikowski, Krishna Prasad, Isabelle Richard-Lordereau, Lothar Roessig, Giuseppe M C Rosano, Warren Sherman, Wendy Gattis Stough, Karl Swedberg, Benoit Tyl, Faiez Zannad, Caroline Boulton, Pieter De Graeff
Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure patients is characterized by a reduction in life expectancy, a progressive decline in health-related quality of life and functional status, as well as a high risk of hospitalization. New approaches are needed to address the unmet medical needs of this patient population. The European Medicines Agency (EMA) is undertaking a revision of its Guideline on Clinical Investigation of Medicinal Products for the Treatment of Chronic Heart Failure...
March 27, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28345158/circular-rnas-in-heart-failure
#7
REVIEW
Yvan Devaux, Esther E Creemers, Reinier A Boon, Stanislas Werfel, Thomas Thum, Stefan Engelhardt, Stefanie Dimmeler, Iain Squire
Cardiovascular disease, and particularly heart failure, is still a serious health care issue for which novel treatments and biomarkers are needed. The RNA family comprises different subgroups, among which the small-sized microRNAs and the larger long non-coding RNAs have shown some potential to aid in moving personalized health care of heart failure patients a step forward. Here, members of the Cardiolinc network review the recent findings suggesting that the less well-known circular RNAs may constitute a novel reservoir of therapeutic targets and biomarkers of heart failure...
March 27, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28344828/lc-ms-ms-assay-for-quantitation-of-enalapril-and-enalaprilat-in-plasma-for-bioequivalence-study-in-indian-subjects
#8
Dhiman Halder, Shubhasis Dan, Murari Mohun Pal, Easha Biswas, Nilendra Chatterjee, Pradipta Sarkar, Umesh Chandra Halder, Tapan Kumar Pal
BACKGROUND: Enalapril (EPL) is an angiotensin-converting enzyme inhibitor for the treatment of hypertension and chronic heart failure. Enalaprilat (EPLT) is an active metabolite that contributes to the overall activity of EPL. AIM: To quantitate EPL along with its metabolite EPLT using LC-MS/MS, a bioanalytical method was developed and validated with tolbutamide in human plasma using a protein precipitation technique. RESULTS: The sensitive and selective method has an LLOQ of 1 ng/ml with a linearity range of 1-500 ng/ml for both EPL and EPLT using 300 µl of plasma without any matrix effect...
March 2017: Future Science OA
https://www.readbyqxmd.com/read/28344419/determinants-of-treatment-modification-in-hypercholesterolemic-patients
#9
Ko-Fan Wang, Cheng-Hsueh Wu, Chun-Chin Chang, Lung-Ching Chen, Kang-Ling Wang, Tse-Min Lu, Shing-Jong Lin, Chern-En Chiang
BACKGROUND: There is a lack of knowledge of those contemporary factors associated with modifying subtherapeutic treatments in hypercholesterolemic patients. The aim of this study was to assess determinants of treatment modification in patients not attaining their low-density lipoprotein cholesterol goals. METHODS: The CEntralized Pan-Asian survey on tHE Under-treatment of hypercholeSterolemia enrolled patients taking stable lipid-lowering medications. The study physicians then determined existing patient treatments, which were to be continued or modified when treatments failed...
March 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/28344417/circulating-adiponectin-levels-following-treatment-can-predict-late-clinical-outcomes-in-chronic-heart-failure
#10
Ho-Ping Yu, Hsu-Lung Jen, Wei-Hsian Yin, Jeng Wei
BACKGROUND: Circulating adiponectin concentration increases in patients with chronic heart failure (HF). We sought to explore the prognostic value of temporal changes in adiponectin concentration following treatment for chronic HF. METHODS: Serum adiponectin levels were measured at baseline and after a 3-month anti-failure treatment in 124 patients with symptomatic chronic systolic HF. Major adverse cardiac events (MACE) including death, heart transplantation, or hospitalization with worsening HF during a median follow-up period of 752 days were determined...
March 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/28344129/role-of-microrna-in-diabetic-cardiomyopathy-from-mechanism-to-intervention
#11
REVIEW
Rui Guo, Sreejayan Nair
Diabetic cardiomyopathy is a chronic and irreversible heart complication in diabetic patients, and is characterized by complex pathophysiologic events including early diastolic dysfunction, cardiac hypertrophy, ventricular dilation and systolic dysfunction, eventually resulting in heart failure. Despite these characteristics, the underlying mechanisms leading to diabetic cardiomyopathy are still elusive. Recent studies have implicated microRNA, a small and highly conserved non-coding RNA molecule, in the etiology of diabetes and its complications, suggesting a potentially novel approach for the diagnosis and treatment of diabetic cardiomyopathy...
March 24, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28344125/capadenoson-a-clinically-trialed-partial-adenosine-a1-receptor-agonist-can-stimulate-adenosine-a2b-receptor-biased-agonism
#12
Jo-Anne Baltos, Elizabeth A Vecchio, Matthew A Harris, Cheng Xue Qin, Rebecca H Ritchie, Arthur Christopoulos, Paul J White, Lauren T May
The adenosine A2B receptor (A2BAR) has been identified as an important therapeutic target in cardiovascular disease, however in vitro and in vivo targeting has been limited by the paucity of pharmacological tools, particularly potent agonists. Interestingly, 2-((6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)-2-pyridinyl)thio)acetamide (BAY60-6583), a potent and subtype-selective A2BAR agonist, has the same core structure as 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitril (capadenoson)...
March 23, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28344049/-serum-potassium-levels-and-long-term-mortality-in-the-elderly-with-hypertension
#13
M Heras Benito, M J Fernández-Reyes, M T Guerrero Díaz, A Muñoz Pascual
There is increasing evidence that small variations within the normal range (3.5-5mEq/L) of potassium are associated with mortality. OBJECTIVE: To determine whether there is an association between serum potassium level (sK) and mortality in a cohort of elderly hypertensive patients. PATIENTS AND METHODS: A retrospective, observational study was conducted on patients who had sK levels available in a period of clinical stability during their recruitment between January and April 2006 and followed-up for 10 years...
March 23, 2017: Hipertensión y Riesgo Vascular
https://www.readbyqxmd.com/read/28343445/a-case-of-anagrelide-induced-nonischemic-cardiomyopathy-in-a-patient-with-essential-thrombocythemia
#14
Pritpal Singh
BACKGROUND: Anagrelide is an established treatment option for essential thrombocythemia (ET). Cardiovascular adverse events can occur with its use including heart failure and cardiomyopathy. CASE REPORT: A 52-year-old African American male with ET presented with chest pain, shortness of breath, and dyspnea on exertion. His ET was managed with hydroxyurea 1500 mg by mouth twice a day and anagrelide 1 mg by mouth 3 times a day. The patient was receiving anagrelide for approximately 2 years prior to presentation...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28343276/an-updated-review-of-cardiac-devices-in-heart-failure
#15
REVIEW
C Murphy, H Zafar, F Sharif
BACKGROUND: Heart failure has the highest rates of adult hospitalisations, the highest mortality rates and significant costs associated with its care. The cost of heart failure is expected continue to grow on a global scale, with $108 billion spent on heart failure in 2012. Mortality rates are high, with incident cases of heart failure resulting in 30% 1-year mortality, and in hospital mortality of acute heart failure, 28%. METHODS AND RESULTS: This article reviews the devices currently in use for the treatment of heart failure, as well as those that are under investigation...
March 25, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28342630/statins-attenuate-but-do-not-eliminate-the-reverse-epidemiology-of-total-serum-cholesterol-in-patients-with-non-ischemic-chronic-heart-failure
#16
Hanna Fröhlich, Nandita Raman, Tobias Täger, Dieter Schellberg, Kevin M Goode, Syed Kazmi, Morten Grundtvig, Torstein Hole, John G F Cleland, Hugo A Katus, Stefan Agewall, Andrew L Clark, Dan Atar, Lutz Frankenstein
BACKGROUND: In patients with chronic heart failure (CHF) increasing levels of total serum cholesterol are associated with improved survival - while statin usage is not. The impact of statin treatment on the "reverse epidemiology" of cholesterol is unclear. METHODS: 2992 consecutive patients with non-ischemic CHF due to left ventricular systolic dysfunction from the Norwegian CHF Registry and the CHF Registries of the Universities of Hull, UK, and Heidelberg, Germany, were studied...
March 9, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28342624/the-level-of-anxiety-depression-and-quality-of-life-among-patients-with-heart-failure-in-greece
#17
Zoi Aggelopoulou, Nikolaos V Fotos, Anastasia A Chatziefstratiou, Konstantinos Giakoumidakis, Ioannis Elefsiniotis, Hero Brokalaki
PURPOSE: The assessment of the level of anxiety, depression and quality of life among patients with heart failure. METHODS: It was an observational study. The populations were 231 patients with heart failure who were hospitalized in cardiology departments of 2 general hospitals in Athens, from September 1, 2010 through January 31, 2012. We used the "Minnesota Living with Heart Failure Questionnaire - MLHFQ" to evaluate patients' quality of life and the " State-Trait Anxiety Inventory - STAI" and the "Maastricht Questionnaire - MQ" to evaluate the level of stress and depression, respectively...
April 2017: Applied Nursing Research: ANR
https://www.readbyqxmd.com/read/28341761/cardiac-safety-of-dual-anti-her2-therapy-in-the-neoadjuvant-setting-for-treatment-of-her2-positive-breast-cancer
#18
Anthony F Yu, Jasmeet C Singh, Rui Wang, Jennifer E Liu, Anne Eaton, Kevin C Oeffinger, Richard M Steingart, Clifford A Hudis, Chau T Dang
BACKGROUND: Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)-positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzumab, and pertuzumab (THP) in the neoadjuvant setting followed by adjuvant trastuzumab-based therapy. METHODS: Fifty-seven patients treated with neoadjuvant dose-dense AC-THP followed by adjuvant trastuzumab-based therapy between September 1, 2013, and March 1, 2015, were identified...
March 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28341415/diuretic-strategies-in-acute-heart-failure-and-renal-dysfunction-conventional-vs-carbohydrate-antigen-125-guided-strategy-clinical-trial-design
#19
Sergio García-Blas, Clara Bonanad, Pau Llàcer, Silvia Ventura, José María Núñez, Ruth Sánchez, Carlos Chamorro, Lorenzo Fácila, Rafael de la Espriella, Juana María Vaquer, Alberto Cordero, Mercè Roqué, Víctor Ortiz, Paolo Racugno, Vicent Bodí, Ernesto Valero, Enrique Santas, María Del Carmen Moreno, Gema Miñana, Arturo Carratalá, Lourdes Bondanza, Ana Payá, Ingrid Cardells, Raquel Heredia, Mauricio Pellicer, Guillermo Valls, Patricia Palau, María José Bosch, Rafael Raso, Andrés Sánchez, Vicente Bertomeu-González, Vicente Bertomeu-Martínez, Vicente Montagud-Balaguer, Cristina Albiach-Montañana, Jezabel Pendás-Meneau, Goitzane Marcaida, Sonia Cervantes-García, Rodolfo San Antonio, Elisabet de Mingo, Francisco J Chorro, Juan Sanchis, Julio Núñez
INTRODUCTION AND OBJECTIVES: The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1...
March 21, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28341373/drugs-to-prevent-sudden-cardiac-death
#20
Julia W Erath, Stefan H Hohnloser
Sudden cardiac death (SCD) remains a major public health burden despite enormous advances in post-resuscitation care, management of structural heart diseases, and antiarrhythmic treatment modalities. Primary and secondary prevention of sudden cardiac death require understanding of the underlying substrate causing ventricular arrhythmias and its modification by pharmacological (i.e. heart failure therapy) or interventional (catheter ablation) methods. Antiarrhythmic drug therapy has experienced ups and downs during the last 30years balancing high antiarrhythmic potential, toxic side effects and pro-arrhythmic potency...
March 18, 2017: International Journal of Cardiology
keyword
keyword
73383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"